Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sabin-IPV + DTaP
- Development stage
- Unknown
- Lead developer
- China National Biotec
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This co-administration regimen involves the simultaneous delivery of two separate vaccines developed by China National Biotec Group Company Limited (CNBG): a Sabin-strain-based inactivated poliovirus vaccine (sIPV) and a diphtheria-tetanus-acellular pertussis (DTaP) vaccine. The sIPV component provides protection against poliovirus types I, II, and III using inactivated Sabin strains, which offers a safer alternative to live-attenuated vaccines while maintaining high immunogenicity. The DTaP component is a combination vaccine containing diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens to prevent whooping cough, diphtheria, and tetanus. Clinical studies, including Phase 4 trials, have demonstrated that the simultaneous administration of these two vaccines in infants is safe and produces a non-inferior immune response compared to separate administration, facilitating the integration of sIPV into the Expanded Programme on Immunization (EPI) in China.
- Other names
- sIPV + DTaPSimultaneous administration of Sabin-IPV and DTaPSabin-IPV + DTaP-China National Biotec Group Company Limited-poliomyelitis-diphtheria-tetanus-pertussis
02
Targets
Host adaptive immune receptors recognizing poliovirus type 1/2/3, diphtheria toxoid, tetanus toxoid, pertussis toxin, filamentous hemagglutinin, and pertactin epitopes
Beyond the preview
Go deeper on Sabin-IPV + DTaP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sabin-IPV + DTaP.